Indications and usage:
Alzheimer disease, dementia syndrome of various origin, post-stroke period, traumatic brain injuries (concussions, maims, brain surgeries).
Contraindications: hypersensitivity to drug components (carbolic acid and its derivatives); severe renal insufficiency; epileptic status; pediatric use under the age of 18 (the is no information on safety and efficacy available); pregnancy and lactation period; ischemic heart disease; heart rhythm disorders.
Dosage and administration:
For parenteral administration. Doses and treatment duration depends on the disease nature and severity, as well as on the age of a patient.
The recommended effective treatment regimen contains regular daily injections for 10-20 days.
Acute conditions (ischaemic stroke, craniocerebral injury, post-neurosurgical complications) – from 10 to 50 ml;
During residual period of cerebral stroke and traumatic brain injury – from 5 to 50 ml;
Psychoorganic syndrome and depression – from 5 to 30 ml;
Alzheimer disease, mental disability of vascular and concomitant Alzheimer-vascular origin – from 5 to 30 ml;
Neuropaediatrics – 1-2 ml/day.
To improve therapy efficacy retreatment courses may be given.
Cerebrolysat is administered in from of injections: intramuscular introduction (up to 5 ml) and intravenous introduction (up to 10 ml). Doses from 10 ml to 50 ml are administered in form of slow intravenous infusions (Cerebrolysat is diluted with solution for infusions). Infusion duration is 15-60 minutes.
Overdosage: there is no information available.
Precautions: Cerebrolysat may be used simultaneously with vitamins and medications improving heart circulation, but these medications should not be mixed in one syringe with Cerebrolysat.